DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Subscribe To Our Newsletter & Stay Updated
